Fennec Pharmaceuticals Inc (NASDAQ:FENC - Get Free Report) Director Rosty Raykov sold 2,431 shares of Fennec Pharmaceuticals stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $4.94, for a total transaction of $12,009.14. Following the sale, the director now owns 66,432 shares of the company's stock, valued at approximately $328,174.08. The sale was disclosed in a document filed with the SEC, which is available through this link.
Rosty Raykov also recently made the following trade(s):
- On Thursday, August 1st, Rosty Raykov sold 2,431 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $6.25, for a total transaction of $15,193.75.
Fennec Pharmaceuticals Stock Down 3.6 %
Fennec Pharmaceuticals stock opened at $4.82 on Wednesday. The company has a quick ratio of 7.75, a current ratio of 8.02 and a debt-to-equity ratio of 9.86. The firm has a market cap of $131.72 million, a P/E ratio of 160.67 and a beta of 0.26. The business has a fifty day moving average of $5.64 and a two-hundred day moving average of $7.31. Fennec Pharmaceuticals Inc has a twelve month low of $4.76 and a twelve month high of $11.92.
Fennec Pharmaceuticals (NASDAQ:FENC - Get Free Report) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of $0.06 by ($0.26). Fennec Pharmaceuticals had a negative return on equity of 53.38% and a net margin of 5.59%. The company had revenue of $7.26 million for the quarter, compared to analysts' expectations of $13.67 million. During the same quarter last year, the company earned ($0.21) earnings per share. On average, analysts forecast that Fennec Pharmaceuticals Inc will post -0.07 earnings per share for the current fiscal year.
Institutional Trading of Fennec Pharmaceuticals
Kamala’s Dirty Election Move… Revealed
From Paradigm Press | Ad
According to former advisor to the CIA, the Pentagon and the White House Jim Rickards…
Kamala and her puppet masters are planning this dirty election move…
Click here now and learn how to prepare.
Several hedge funds have recently modified their holdings of FENC. Acadian Asset Management LLC purchased a new position in shares of Fennec Pharmaceuticals in the 2nd quarter worth approximately $49,000. The Manufacturers Life Insurance Company acquired a new stake in Fennec Pharmaceuticals in the second quarter valued at approximately $69,000. Rhumbline Advisers boosted its stake in Fennec Pharmaceuticals by 44.7% in the second quarter. Rhumbline Advisers now owns 29,110 shares of the company's stock valued at $178,000 after acquiring an additional 8,987 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in Fennec Pharmaceuticals by 67.7% in the first quarter. BNP Paribas Financial Markets now owns 32,769 shares of the company's stock worth $364,000 after purchasing an additional 13,223 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its position in shares of Fennec Pharmaceuticals by 71,275.0% during the first quarter. Russell Investments Group Ltd. now owns 34,260 shares of the company's stock worth $381,000 after purchasing an additional 34,212 shares in the last quarter. 55.51% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several brokerages recently issued reports on FENC. Wedbush reissued an "outperform" rating and issued a $14.00 price objective (down previously from $16.00) on shares of Fennec Pharmaceuticals in a research note on Tuesday, August 13th. Craig Hallum cut their price target on Fennec Pharmaceuticals from $17.00 to $15.00 and set a "buy" rating on the stock in a research note on Wednesday, August 14th. Finally, HC Wainwright lowered their price objective on shares of Fennec Pharmaceuticals from $15.00 to $13.00 and set a "buy" rating for the company in a research note on Thursday, August 22nd.
Read Our Latest Stock Analysis on Fennec Pharmaceuticals
Fennec Pharmaceuticals Company Profile
(
Get Free Report)
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
